Sort
53,477 grants matching “addiction”
Kappa Opioid Antagonist for Cocaine Addiction
$715,572Frank I Carroll · Research Triangle Institute · U19 · FY2006 · DA
Non-opiate treatment after prenatal opiate exposure to Prevent Postnatal Injury to the Young Brain (No-POPPY)
$715,386Henrietta S. Bada · University Of Kentucky · R01 · FY2021 · DA
CLINICAL TRIAL: NEW MEDICATIONS TO TREAT ALCOHOL DEPENDENCE
$715,252Bankole A Johnson · University Of Virginia · M01 · FY2008 · RR
Multivariate genome-wide association analysis of opioid-related traits in half a million diverse individuals
$715,238Sandra Sanchez Roige · University Of California, San Diego · R01 · FY2025 · DA
PASSIVE IMMUNITY TO COCAINE USING NOVEL HUMAN ANTIBODIES
$715,114University Of Cincinnati · U19 · FY2000 · DA
South Carolina Consortium of the Clinical Trials Network
$715,106Kathleen Theresa Brady · Medical University Of South Carolina · U10 · FY2009 · DA
Synthetic Psychoactive "Bath Salt" Effects on Brain Activity and Behavior
$715,015Stephen John Kohut · Mclean Hospital · R01 · FY2019 · DA
A Reduced Complexity Cross in BALB/c substrains to identify the genetic basis of oxycodone dependence phenotypes
$714,936Camron D Bryant · Boston University Medical Campus · U01 · FY2022 · DA
Evaluation of Opioid Antagonist Activity in Humans
$714,902Eric C Strain · Johns Hopkins University · R01 · FY2010 · DA
Virtual systemic identification of drug targets of obesity candidate genes
$714,892Yingchang Lu · Vanderbilt University Medical Center · R01 · FY2024 · DK
Twin Family Study of Vulnerability to Substance Abuse
$714,877William G Iacono · University Of Minnesota · R37 · FY2015 · DA
TRANSCRIPTOME AND EPIGENOME MAPPING IN DOPAMINE NEURONS FROM THE OPIOID EXPOSED HUMAN BRAIN
$714,720Schahram Akbarian · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · DA
Internal Dynamics of the Postsynaptic Density
$714,476Thomas A Blanpied · University Of Maryland Baltimore · R37 · FY2022 · MH
Prazosin Treatment for Alcohol Use Disorder with Alcohol Withdrawal Symptoms
$714,133Rajita Sinha · Yale University · R01 · FY2024 · AA
NPQ/Spexin the Endogenous Ligand for the Galanin Receptor 3
$714,012Akihiko Ozawa · Torrey Pines Inst For Molecular Studies · R01 · FY2017 · DA
Oral v Injection Naltrexone in Hospital: Comparative Effectiveness for Alcoholism
$713,958Richard Saitz · Boston University Medical Campus · R01 · FY2014 · AA
Optimizing HIV-care-continuum engagement and outcomes among opioid users
$713,846Kenzie Preston · National Institute On Drug Abuse · ZIA · FY2017 · DA
Integrated vs. Separate Care for Hepatitis C, Substance Abuse, and HIV Prevention
$713,797Brian R. Edlin · Suny Downstate Medical Center · R01 · FY2010 · DA
Addiction Telemedicine Consultation in Primary Care: Increasing Access to Pharmacotherapy and Specialty Treatment for Alcohol Problems
$713,762Stacy Ann Sterling · Kaiser Foundation Research Institute · R01 · FY2020 · AA
RADIOTRACER R &D IN NUCLEAR MEDICINE AND NEUROSCIENCES
$713,640Brookhaven Science Assoc-Brookhaven Lab · R01 · FY2004 · EB
Genetic Variation in Opioid Induced Respiratory Depression in Mice
$713,335Jason A Bubier · Jackson Laboratory · R01 · FY2022 · DA
Internal Dynamics of the Postsynaptic Density
$713,306Thomas A Blanpied · University Of Maryland Baltimore · R37 · FY2020 · MH
PTSD and Addiction Disorder Screening and Treatment for Incarcerated Men
$713,275Nancy Wolff · Rutgers, The State Univ Of N.J. · R01 · FY2012 · MH
Risks for Transitions in Drug use Among Urban Adults
$713,244William W Eaton · Johns Hopkins University · R01 · FY2007 · DA
A Systems Biology Approach to HIV-associated Neurocognitive Impairment: Role of Drug Abuse and Neuroinflammation
$713,234David Martin Murdoch · Duke University · R01 · FY2018 · DA